Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.66 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | NAMPT | P43490 | 1/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13593340 | 1.00 | NAAA (0.70) | NAAAALDH1A1HTTNPC1MAPT | |
| SCHEMBL6383063 | 1.00 | NAAA (0.70) | NAAAALDH1A1HTTNPC1MAPT | |
| Salcaprozic Acid SCHEMBL29385752 | 1.00 | NAAA (0.70) | NAAAALDH1A1HTTNPC1MAPT | |
| SCHEMBL2331916 | 1.00 | NAAA (0.70) | NAAAALDH1A1HTTNPC1MAPT | |
| Salcaprozic Acid SCHEMBL4586235 | 1.00 | NAAA (0.70) | NAAAALDH1A1HTTNPC1MAPT | |
| SCHEMBL14088979 | 1.00 | NAAA (0.70) | NAAAALDH1A1HTTNPC1MAPT | |
| SCHEMBL14088978 | 1.00 | NAAA (0.70) | NAAAALDH1A1HTTNPC1MAPT | |
| Salcaprozic Acid SCHEMBL845833 | 0.98 | NAAA (0.68) | NAAAALDH1A1HTTNPC1MAPT | |
| Salcaprozic Acid SCHEMBL2159928 | 0.98 | NAAA (0.68) | NAAAALDH1A1HTTNPC1MAPT | |
| SCHEMBL2331880 | 0.98 | NAAA (0.68) | NAAAALDH1A1HTTNPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4299052-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND A PERMEATION ENHANCER | Adocia (FR) | 2024-01-03 | — | — | EP | claimed |
| CN-116850132-A | Formulations of active agents for oral administration | 安提拉生物有限公司 | 2023-10-10 | — | — | CN | claimed |
| CN-116831978-A | Formulations of active agents for oral administration | 安提拉生物有限公司 | 2023-10-03 | — | — | CN | claimed |
| CN-116831977-A | Formulations of active agents for oral administration | 安提拉生物有限公司 | 2023-10-03 | — | — | CN | claimed |
| WO-2023161938-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF KAPPA OPIOID RECEPTOR AGONIST PEPTIDE | ENTERA BIO LTD. (IL) | 2023-08-31 | — | — | WO | claimed |
| WO-2023161937-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF GLUCAGON-LIKE PEPTIDE-2 | ENTERA BIO LTD. (IL) | 2023-08-31 | — | — | WO | claimed |
| WO-2023161939-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF GLUCAGON-LIKE PEPTIDE-1 AND ANALOGS THEREOF | ENTERA BIO LTD. (IL) | 2023-08-31 | — | — | WO | claimed |
| WO-2023161936-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF GROWTH HORMONE-RELEASING HORMONE | ENTERA BIO LTD. (IL) | 2023-08-31 | — | — | WO | claimed |
| WO-2023161935-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF GROWTH HORMONE | ENTERA BIO LTD. (IL) | 2023-08-31 | — | — | WO | claimed |
| WO-2023161934-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ENTERA BIO LTD. (IL) | 2023-08-31 | — | — | WO | claimed |
| US-20100210526-A1 | ORAL ADMINISTRATION OF A CALCITONIN | JOSHI YATINDRA | 2010-08-19 | — | — | US | claimed |
| EP-2131810-A2 | ORAL ADMINISTRATION OF A CALCITONIN | Novartis Ag (CH) | 2009-12-16 | — | — | EP | claimed |
| US-7569539-B2 | Oral administration of calcitonin | NOVARTIS AG (CH) | 2009-08-04 | — | — | US | claimed |
| WO-2008109385-A2 | ORAL ADMINISTRATION OF A CALCITONIN | NOVARTIS AG (CH) | 2008-09-12 | — | — | WO | claimed |
| US-20070232524-A1 | Oral administration of calcitonin | NOVARTIS AG (CH) | 2007-10-04 | — | — | US | claimed |
| WO-2006124047-A9 | PHARMACEUTICAL FORMULATIONS CONTAINING MICROPARTICLES OR NANOPARTICLES OF A DELIVERY AGENT | EMISPHERE TECH INC (US) | 2007-06-21 | — | — | WO | claimed |
| US-20060135402-A1 | Oral administration of calcitonin | AZRIA MOISE | 2006-06-22 | — | — | US | claimed |
| EP-1149066-B1 | METHOD OF PREPARING ALKYLATED SALICYLAMIDES | EMISPHERE TECH INC (US) | 2005-11-09 | — | — | EP | claimed |
| EP-1526871-A1 | ORAL ADMINISTRATION OF CALCITONIN | Novartis AG (CH) | 2005-05-04 | — | — | EP | claimed |
| WO-2004012772-A1 | ORAL ADMINISTRATION OF CALCITONIN | NOVARTIS AG (CH) | 2004-02-12 | — | — | WO | claimed |